Global Precision Oncology Market Growth (Status and Outlook) 2023-2029

Global Precision Oncology Market Growth (Status and Outlook) 2023-2029

The global Precision Oncology market size is projected to grow from US$ 93420 million in 2022 to US$ 184230 million in 2029; it is expected to grow at a CAGR of 10.2% from 2023 to 2029.

Precision oncology has led to significant advances in cancer treatment, particularly in the treatment of rare and hard-to-treat cancers. It has helped reduce the side effects of cancer treatment by minimizing the use of chemotherapy and other treatments that may not be effective for a particular patient’s tumor.

Precision oncology is a field of medicine that uses genetic information to adapt cancer treatment to an individual’s specific tumor and biology. It is also known as personalized medicine or precision medicine. Precision oncology identifies the unique genetic mutations and other molecular characteristics of a patient’s tumor, and then uses that information to choose the most effective treatment. This approach takes into account the genetic differences between tumors and the genetic variations among individuals and allows for targeted and effective treatment options. Precision oncology techniques include genomic profiling, which analyzes the genetic makeup of a tumor, and liquid biopsies, which detect tumor DNA in the bloodstream. This information can be used to match patients with targeted therapies that are designed to specifically target the molecular abnormalities in their tumor.

LPI (LP Information)' newest research report, the “Precision Oncology Industry Forecast” looks at past sales and reviews total world Precision Oncology sales in 2022, providing a comprehensive analysis by region and market sector of projected Precision Oncology sales for 2023 through 2029. With Precision Oncology sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Precision Oncology industry.

This Insight Report provides a comprehensive analysis of the global Precision Oncology landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Precision Oncology portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Precision Oncology market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Precision Oncology and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Precision Oncology.

This report presents a comprehensive overview, market shares, and growth opportunities of Precision Oncology market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Diagnostics
Therapeutics

Segmentation by application
Pharmaceutical & Biotechnology Companies
Hospitals & Diagnostic Laboratories
Healthcare Data Companies

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Acrivon Therapeutics
Bio-Serv
Exact Sciences Corporation
Illumina, Inc.
Invitae Corporation
Laboratory Corporation of America
QIAGEN
Rain Oncology
Relay Therapeutics
Strata Oncology, Inc.
Thermo Fisher Scientific Inc.
Variantyx, Inc.

Please note: The report will take approximately 2 business days to prepare and deliver.